Work

Toward a More accurate, Evidence‐Based Classification of CYP Inhibitors: A Critical Appraisal of Current Systems

Year: 2025

Type: article

Abstract: In this issue of CPT, Malavé et al. deliver a comprehensive reassessment of CYP2C19 inhibitor classifications through a systematic review of clinical drug-drug interaction (DDI) studies. While their findings bring clarity to specific discrepancies, this commentary explores the origins of such inconsistencies, particularly focusing on methodological, pharmacogenetic, and substrate-specific complexities. These issues prompt renewed consideration of how CYP inhibitor categories are defined, communicated, and used in clinical and regulatory settings.

Source: Clinical Pharmacology & Therapeutics

DOI: 10.1002/cpt.70122

Author: Janne T. Backman

Institutions: University of Helsinki, Helsinki University Hospital, Hospital District of Helsinki and Uusimaa

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,410